Maryland Capital Management Amgen Inc Transaction History

Maryland Capital Management

$1.2 Billion
Q3 2022

A detailed history of Maryland Capital Management transactions in Amgen Inc stock. As of the latest transaction made, Maryland Capital Management holds 5,796 shares of AMGN stock, worth $1.85 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

5,796

Previous 3,296 75.85%

Holding current value

$1.85 Million

Previous $802,000 62.84%

% of portfolio

0.11%

Previous 0.06%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $561,150 - $632,875	2,500 Added 75.85%	5,796 $1.31 Million
Q2 2022 Aug 11, 2022	SELL	$230.71 - $256.74 $34,837 - $38,767	-151 Reduced 4.38%	3,296 $802,000
Q1 2022 May 12, 2022	SELL	$219.27 - $242.57 $83,541 - $92,419	-381 Reduced 9.95%	3,447 $834,000
Q4 2021 Feb 11, 2022	SELL	$198.88 - $227.6 $35,997 - $41,195	-181 Reduced 4.51%	3,828 $861,000
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $7,217 - $8,455	34 Added 0.86%	4,009 $852,000
Q2 2021 Aug 13, 2021	BUY	$233.58 - $259.14 $17,518 - $19,435	75 Added 1.92%	3,975 $969,000
Q1 2021 May 11, 2021	SELL	$221.91 - $258.6 $4,438 - $5,172	-20 Reduced 0.51%	3,900 $970,000
Q4 2020 Feb 11, 2021	SELL	$216.38 - $257.67 $46,738 - $55,656	-216 Reduced 5.22%	3,920 $901,000
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $65,702 - $73,066	-280 Reduced 6.34%	4,136 $1.05 Million
Q2 2020 Aug 12, 2020	BUY	$197.81 - $242.74 $133,917 - $164,334	677 Added 18.11%	4,416 $1.04 Million
Q1 2020 May 13, 2020	BUY	$182.24 - $241.7 $481,660 - $638,813	2,643 Added 241.15%	3,739 $758,000
Q4 2019 Feb 11, 2020	BUY	$189.21 - $243.2 $207,374 - $266,547	1,096 New	1,096 $264,000

Others Institutions Holding AMGN

# of Institutions

3,055

Shares Held

409M

Call Options Held

7.19M

Put Options Held

6.26M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Maryland Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Maryland Capital Management with notifications on news.

Account

Maryland Capital Management Amgen Inc Transaction History